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SUMMARY
In chapter I, we recalled that intracardiac defects can only be corrected
when cardiopulmonary circulation is maintained by exffacorporeal circulation
and ventilation. To prevent clot formation in this artificial circuit, the so-
callled cardiopulmonary bypass (CPB), we completely depend on the
anticoagulatory properties of heparin. Heparin inhibits the clotting system,
which is triggered via the intrinsic pathway by blood-material interaction.
Blood-material interaction alsoactivatesthekinin, plasmin, andcomplement
systems. These systems are all part of the host defense mechanism where
platelets and leucocytes are instrumental in maintaining local hemostasis
and preventing infiltration by micro-organisms. During CPB, foreign surfaces
activate these systems massively and systemically. This activation induces
the so-called whole body inflammatory response (WBIR), which frequently
results in impaired hemostasis and organ dysfunction.
Since 1985, we have been performing clinical studies on the WBIR at the
Onze Lieve Vrouwe Gasthuis (OLVG) in Amsterdam in co-operation with
the research division of the Department of Cardiopulmonary Surgery in
Groningen. To evaluate the process of impaired hemostasis experienced in
cardiac surgery on an every-day basis, first the basic mechanisms of
hemostasis have to be understood. For this reason, recent textbooks and
keynote articles have been studied (chapter II), our results of clinical studies
done in the past have been re-analysed (chapter III and IV and addendum),
and the interpretation of results obtained in our recent clinical studies
(chapter V, VI and VII) are presented. By this process of evaluation, a novel
view on the hemostatic alterations and modifications in CPB was developed.
In chapter II, the hemostatic mechanisms relevant for the cardiac surgeon
were described. Hemostasis is regulated locally by the concerted action of
vessel wall, platelets, and activated plasmatic systems. This action is
regulated by thrombin, which is the back bone of hemostasis. Exposure of
subendothelium caused by vessel wall damage initiates a hemostatic process
in the following sequence.
By means of its adhesive receptor (GPIb) and via the vWF, platelets
adhere to the subendothelium. Subendothelium releases tissue factor and
activates the extrinsic clotting pathway. The first traces of thrombin bind to
the GPIb receptor. The thus activated platelet expresses its GPIIbIIIa
































































action of thrombin is cleaving fibrinogen into fibrin, resulting in the
formation of a consolidated hemostatic plug. This process is balanced by
fibrinolysis. Consequently, hemostaticplugformation is restrictedtothe site
of the vessel wall damage only.
During CPB, the sequence of the above-described process is different.
Traces of thrombin are generated via contact-induced intrinsic clotting,
despite systemic heparinzation. Because thrombin has a higher affinity for
GPIb than for fibrinogen, these traces primarily bind and cleave platelet
adhesive receptors, thus affecting the hemostatic function of platelets. The
GPIIbItra receptor simultaneously expressed by thrombin is also capable of
binding to vWF and may (partly) serve as a back-up mechanism for platelet
adhesion. However, this is no compensation for the massive functional
decrease of GPIb.
In chapter III, the alterations in hemostasis during CPB were described.
We re-analyzed the biochemical data collected for various clinical studies
that we did in the past. First, two phases of increased fibrinolytic activity
were observed: one in conjunction with heparin administration, another after
releasing the aortic cross clamp. The observations of blood oozing in a "dry"
operationfieldafterheparinadministrationandheparinenhancingfibrinolytic
activity are already sufficient to necessitate the search forbetter anticoagulants.
More importantly, we noticed that despite high systemic heparinization
thrombin generation is not completely blocked.
Therefore, the observed decrease of GPIb receptors immediately after the
onset of CPB could, indeed, be caused by thrombin generation. The increase
of a specific molecular marker for disseminated intravascular coagulation
(DIC) right from the start of CPB indicates that this pattern, modified by the
presence of heparin, should be regarded as the initiation of an acute DIC
process.
InchapterIV, previous results of ourstudyon theeffectof the antiprotease
aprotinin on hemostasis in CPB were reviewed. Next to its known
antifibrinolytic effect, aprotinin has a synergistic effect with heparin on the
intrinsic clotting and prevents thrombin generation by contact activation. In
the presence of aprotinin, the specific marker for DIC was completely
inhibited, GPIb platelet receptors were preserved, and hemostasis improved.
These effects suggest once more the prominent role of thrombín ín the
process towards affected hemostasis during CPB. Since 2.106 KIU of
aprotinin added to the pump prime is enough to inhibit thrombin generation,
to preserve GPIb platelet receptors, and to improve hemostasis, the initial
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recommended 6.106 KIU high continuous dose scheme is redundant.
Moreover, because the antifibrinolytic effect of aprotinin disturbs the
physiological balance between fibrinolysis and clotting, there is a danger of
clot formation when aprotinin is given during periods when patients are not
anticoagulated as happens when the 6.106 KIU dose scheme is adopted.
In chapter V, the protocol of two recent studies was described.
In chapter VI, the hemostatic effect of ASA treatment with and without
aprotinin was evaluated. Patients receiving ASA showed significantly
increased platelet degranulation and further impairment of platelet function
during CPB. In ASA-treated patients, aprotinin prevented both these effects.
In addition, aprotinin preserved GPIb platelet receptors and improved
hemostasis equally well in ASA-treated patients as in non-ASA-treated
patients. Therefore, thrombin is likely the common agonist that causes both
the excessive platelet release reaction and the additional impairment of
platelet function in ASA-treated patients.
In chapter VII, the possible role of the thrombin-platelet interaction in
blood loss during CPB was further evaluated. We observed that patients
whose pre-operative platelet numbers were higher than the 50th percentile
lost significantly less blood than patients with lower numbers. Aprotinin
treatment only significantly reduced blood loss in patients with the lower
platelet numbers. Our interpretation is that under systemic heparinization a
limited amount of thrombin is generated which will affect a limited number
of platelets.
When relatively high pre-operative platelet numbers are available,
sufficient unaffected platelets persist to maintain normal hemostasis but not
when a patient has a low platelet number to start with. However, in the
situation where aprotinin is administered, inhibition of thrombin generation
will preserve the platelet adhesive function and thus hemostasis.
By varying the timing of aprotinin administration, we tried to further
pinpoint the mechanism of its effect on hemostasis.
Administering similar doses of aprotinin during the entire pre-CPB
period, or a single dose synchronous with heparin administration, or a dose
only to the pump prime, all caused a similarly significant reduction in post-
operative blood loss. This is consistent with the hypothesis that aprotinin
acts via its synergistic effect on the inhibition of intrinsic clotting that is
caused by contact activation induced by the heart-lung machine.
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